$HIMS
观点汇总
由 AI 根据下方全部推文生成，仅为阅读辅助，以原推为准
Sereny 对 HIMS 的核心论点基于其作为盈利且高增长公司的基本面优势，特别是通过收购 Zava 在欧洲获得超 130 万客户，以及营收的高速增长。他极度看重超过 40% 的空头比率，认为这是引发空头挤压的关键瓶颈，并批评对冲基金做空此类优质资产是愚蠢行为。其观点随时间演变：初期在 45 美元附近买入并视为轻松持有标的；中期因特朗普推出政府药品网站等逆风因素，在 60 美元左右减仓，认为短期承压但长期看涨；后期在 50 美元附近因 CEO 减持导致的恐慌中再次加仓，视波动为机会。他明确表态在回调时买入，利用高隐含波动率卖出看跌期权以获取权利金，并长期将其作为“登月”组合中的健康板块核心持仓，坚信空头最终将回补。
相关推文
共 128 条 · 按时间倒序 · 滚到底自动加载更多
-
解释自己受欢迎部分来自关注关键瓶颈而非卖社区或技术分析。
回复 @VJNCapital：我刚加入时，主要是一些人在卖昂贵社区付费墙或技术分析。 如果有人公开 thesis，大家都挤在同样的大股票 $PYPL 或 $UNH 上。或者追 $HIMS 这样的热门名字。 我受欢迎的很大一部分原因，是专注于关键……
英文原文
@VJNCapital When I first joined it was primarily folks trying to sell expensive community paywalls or TAs. Everyone crowded around the same large stock $PYPL or $UNH investing if they had public thesis. Or hype names like $HIMS. Large part of my popularity was focusing on critical
-
批评伪专家只会堆术语不懂底层技术
我百分之百确定，如果现实里见到你们这些“photonic memory（光子内存）”专家，500 个里有 498 个都讲不清 CXL 内存池化、KV cache 基础设施，以及 $PENG 到底是怎么从中变现的。 这就是为什么我现在时间线上总能看到一堆和技术无关的 $RKLB、$HIMS，或者非技术型 AI 专家。 你们在我的帖子下面胡乱评论，把 M7U MOCVD capex 和 $TSEM 这些完全不相关的东西说错，或者把每个术语都混成像 $SMCI 集成商那样，还硬往 photonics IP 上套。 然后就在我每条帖子下面塞满 buzzword。
英文原文
I'm 100% sure if I met all you "photonic memory" experts in real life. 498 out of 500 of you couldn't explain CXL memory pooling or KV cache infrastructure and what $PENG actually does to derive revenue off that. This is why I'm seeing all these random $RKLB, $HIMS, or non technical AI experts on my timeline now. Backseat commenting completely wrong things about M7U MOCVD capex and $TSEM that aren't related. Or conflating every single term like an $SMCI integrator with photonics IP. Then just pitching buzzwords every under every one of my posts.
-
别拿 HIMS 的药和 TSM 的 FAU 供应商相比
@mrng2019 为什么要把 $HIMS 的睾酮药片，和 $TSM 的 COUPE FAU 供应商放在一起比呢。
英文原文
@mrng2019 Why are we comparing $HIMS testosterone pills with the $TSM FAU supplier for COUPE.
-
两周等权收益回顾
先放这儿…… 如果等权计算，两周回报会是 +15.02%。 在 30 只不同股票上……大多是中大盘。 1. $INTC +29.62% 2. $MRVL +40.95% 3. $TSM +4.72% 4. $COHR +18.9% 5. $RKLB +26.76% 6. $DRAM +12.29% 7. $AVGO +18.32% 8. $AMZN +9.17% 9. $ARM +36.6% 10. $TSEM -1.25% 11. $IBIT +7.68% 12. $NBIS +15.22% 13. $GOOGL +6.41% 14. $AMKR +32.25% 15. $HOOD +19.14% 16. $CRCL +17.58% 17. $META +4.9% 18. $LITE -5.28% 19. $LPTH +20.23% 20. $FN +11.54% 21. $JBL +15.45% 22. $MP +17.48% 23. $HIMS +42.53% 24. $SMTC +18.83% 25. $POWL +9.26% 26. $VPG +17.44% 27. $MOG.A -3.96% 28. $MSFT +11.44% 29. $CVX -1.47% 30. $XLU -2.29% 显然时间周期很短，但我预计这些里面很多还会继续上涨。 如果你在特定名字的下跌时点位进场，而不是一口气同时做多，结果可能会更高。 也不算差吧？
英文原文
Just putting out there... Would have been +15.02% in 2W equal-weighted return. On 30 different stocks... mostly medium-large cap. 1. $INTC +29.62% 2. $MRVL +40.95% 3. $TSM +4.72% 4. $COHR +18.9% 5. $RKLB +26.76% 6. $DRAM +12.29% 7. $AVGO +18.32% 8. $AMZN +9.17% 9. $ARM +36.6% 10. $TSEM -1.25% 11. $IBIT +7.68% 12. $NBIS +15.22% 13. $GOOGL +6.41% 14. $AMKR +32.25% 15. $HOOD +19.14% 16. $CRCL +17.58% 17. $META +4.9% 18. $LITE -5.28% 19. $LPTH +20.23% 20. $FN +11.54% 21. $JBL +15.45% 22. $MP +17.48% 23. $HIMS +42.53% 24. $SMTC +18.83% 25. $POWL +9.26% 26. $VPG +17.44% 27. $MOG.A -3.96% 28. $MSFT +11.44% 29. $CVX -1.47% 30. $XLU -2.29% Obviously short timeframe, but I expect many of these to keep going up more. And probably would have been higher if you time the drop on specific names, rather than going long all at once. Not too shabby?
-
HIMS 开始被注意到
看起来 $HIMS 终于开始被注意到了，今天涨了 +8.64%。 肽业务和收购都在起飞？ 让我有点意外的是，虽然基本面在改善，SI 还保持在 36%。 我很想看看多头和空头最后会怎么演。
英文原文
Looks like $HIMS is finally getting some attention, up +8.64% today. Peptide arc and acquisitions go brrr? Caught me by surprise why the SI is still 36% despite improving fundamentals. I’m very curious to see how this all plays out with the longs vs. shorts. https://t.co/CtpscjKIxl
-
TTD/HIMS/RDDT 都有均值回归机会
像 $TTD 在 22 美元这样的价位是有吸引力的，大概还有 40% 到 50% 的上行空间，能回到低 30 美元。 $HIMS 在 28 美元也差不多，我能看到它均值回归到 40 美元。 还有 $RDDT，我在 140 美元附近做多，现在也还可以。
英文原文
Stuff like $TTD at $22 is compelling, probably 40-50% upside back to low 30's.. Same with $HIMS at $28, I can see mean reversion to $40. And $RDDT at $163, went long around $140, posted some thesis on the way down to $125, but glad it's recovered a bit. Could probably chop a bit but I do see it recovering to $200+ in better macro.
-
认为它至少会慢慢回到 40 美元。
@realstockfox 我觉得它至少会随着时间回到 40 美元左右吧？我们等等看。
英文原文
@realstockfox I think it at least recovers to $40 over time? We’ll see
-
澄清自己谈的是 HIMS 和药片，并确认有持仓。
@commieserenity 这个问题问得有点怪，因为我说的是 $HIMS 和他们的药片。 不过是的，我有持仓，之前也已经披露过了。
英文原文
@commieserenity Thats a weird question to ask considering I’m talking about $HIMS and their pills. But yes I have positions, as I’ve disclosed earlier
-
HIMS 还是太低估
即便在以下情况之后，$HIMS 仍然下跌了 44%，这件事还是挺不可思议的： 1. $NVO 去风险化 + 合作 2. 多项全球收购扩大了 DTC 分销网络 3. 肽类叙事，Huberman 还说在这些条件下 HIMS 会起飞 4. 进入了更友好的宏观环境 5. 空头比例达到了不可持续的 36%+ 好消息是：空头比例不可能占流通盘太多……所以随着时间推移，回补本身就会形成买盘压力，只要基本面改善，向下空间也会被限制住。
英文原文
It’s still pretty incredible $HIMS is down 44% even after: 1. $NVO de-risking + partnership 2. Multiple global acquisitions expanding DTC distribution network 3. Peptide arc, with Huberman saying HIMS was set to soar under these conditions 4. Entering a friendlier macro climate. 5. Short interest reaching unsustainable 36%+ The good news is: short interest can only be so much of the float… So it’s inherent buying pressure to cover over time, which does limit downside if fundamentals improves.
-
说 Huberman 也认为 HIMS 会大涨。
Huberman 的确说过 $HIMS 在今天这种走势里会一路上去…… 看到斯坦福教授怎么看公开市场股票，也挺有意思的。 https://t.co/jqVtpEaoGB
英文原文
Huberman did say $HIMS was set to soar… in this type of arc playing out today. Interesting to see takes from Stanford professors on public equities. https://t.co/jqVtpEaoGB
-
确认自己有 HIMS 持仓。
@Yolo365247isme 我有 $HIMS 的持仓。
英文原文
@Yolo365247isme I have positions in $HIMS.
-
提到 Huberman 上月说 HIMS 会因 peptides 起飞。
@Ud197601 不太确定……不过 Andrew Huberman 上个月确实说过，在这种情况下，$HIMS 会因为 peptides 而起飞。 https://t.co/ARknCoXMX6
英文原文
@Ud197601 Not quite sure... But Andrew Huberman did say $HIMS was set to soar from peptides last month in this type of scenario. https://t.co/ARknCoXMX6
-
称该公告是 HIMS 收入再加速的最强催化。
这条公告是到目前为止最利好 $HIMS 收入再加速的催化剂。 而且背景还是： - 流通盘有 30%+ 被做空 - 新的 $NVO 合作 / 诉讼刚出 - 新的全球并购 - 宏观环境回暖。 股价现在仍只有 25 美元，低于去年 70 美元。 做空者很可能要麻烦了： $HIMS 可以以他们复合产品常见的 70%-80% 毛利率，去抢占 peptides 这个“灰色市场” TAM 的理想蛋糕。 - 例如：Healing：BPC-157 和 Thymosin beta-4 - 头发与皮肤：GHK-Cu - 减重与增肌：MOTS-c 和 Ibutamoren 而且借助新的并购，它们现在大概成了全球最大的独立 DTC 分销网络…… 所以只要跑一个 peptide 方案订阅，每位订户每月 150 到 300 美元，20 万订户就是 3.6 亿美元以上的高毛利 ARR。 这还只是一个例子，但现在它们已经有全球客户网络了。 去年他们还烧了 capex 去收购 peptide 生产设施……现在这已经变成一个巨大的现金奶牛业务。 我之前就说过，$HIMS 要让空头回补，需要基本面发生变化，而这条消息大概就是市场数据上看到的那个信号。 而 $HIMS 正在因为监管去风险而变成一家基本面更扎实的公司。
英文原文
This announcement is the most bullish catalyst for $HIMS revenue re-acceleration to date. This is amid: - 30%+ of the float sold short - new $NVO partnership/lawsuit dropped - new global acquisitions - recovering macro climate. The share price is still $25, down from $70 last year. Short sellers are likely in trouble: $HIMS can capture market share at the ~70%-80% gross margins typical of their compounded products for the holy grail of the "Grey Market" TAM for peptides. - EG. Healing: BPC-157 and Thymosin beta-4 - Hair & Skin: GHK-Cu - Weight Loss & Muscle: MOTS-c and Ibutamoren And now they're probably the world's largest independent DTC distribution network to date from their new acquisitions... So just running a peptide protocol subscription between $150 to $300, for 200k subscribers is $360M+ in high-margin ARR. As just one example, but now they have a worldwide net of customers. They burned through capex last year to acquire peptide manufacturing facilities too... so now that's turned into a massive cash-cow business. I said $HIMS would need fundamental changes in order to force shorts to cover, and this is probably that signal as seen with market data. And $HIMS is turning into a fundamentally sound company after regulatory de-risking.
-
博主列出30只看好的美股并简述理由，涵盖AI半导体、太空、机器人、加密等领域
今天随机列出30只美国可投资的股票以及我喜欢它们的理由： 1. $INTC——美国晶圆代工的希望，国家安全 2. $MRVL——未来的maia芯片和CPO等附加产品推动营收规模化，业务范围太多数不过来 3. $TSM——半导体/AI的支柱 4. $COHR——业务全垂直整合 + 捕获光学周期 5. $RKLB——太空领域的终极前沿，5年后和20年后都会存在 6. $DRAM——三星/SK海力士的内存敞口 7. $AVGO——超大规模云商不喜欢英伟达GPU税 8. $AMZN——没人能竞争得过隔夜送达卫生纸这件事。机器人技术会长期降低运营费用 9. $ARM——AGI CPU在未来十年会大幅提升营收 10. $TSEM——做光相关的东西你需要晶圆代工 11. $IBIT——比特币，这点我们现在已经众所周知了 12. $NBIS——我认为它是下一个AWS。此外它们还与优步合作做自动驾驶，拥有可扩展的数据库公司、数据标注业务。几乎像一个小谷歌。 13. $GOOGL——youtube不会消失，gemini很棒。它们通过TPU实现垂直整合，用运营收入资助基础设施建设，所以我看好它。 14. $AMKR——超级工厂将在2027-2028年末投产。受益于美国制造政策 15. $HOOD——短期我不喜欢，但长期我看好罗宾汉，因为他们抓住了散户 + 有更多产品如银行等正在规模化。产品创新很疯狂。 16. $CRCL——我恰好非常喜欢稳定币，并认为它们是支付和持有的未来（取决于澄清法案的进展） 17. $META——人们不会很快停止使用Instagram、Whatsapp或其他应用。 18. $LITE——$GOOGL TPU敞口在BOM中占比较高。只要谷歌的AI计划持续运行，我认为$LITE会表现良好。 19. $LPTH——锗和中国出口管制问题将持续存在，因此美国制造的工程替代品将始终重要。 20. $FN——总得有人来组装光学产品 21. $JBL——同上，但加上英特尔硅光业务的IP，可能会成为innolight那样的公司 22. $MP——美国稀土项目极其重要，类似于$INTC涉及的国家安全风险 23. $HIMS——听我说，他们刚收购了一堆公司，股价在$19时有全球DTC渠道。做空者非常讨厌这家公司，但我认为作为逆向多头它实际上很有前景。 24. $SMTC——LRO/LPO转型 25. $POWL——美国版hammond，用于开关设备DC类瓶颈的替代方案 26. $VPG——人形机器人未来会成为主流，大概2027-2028年，这家公司做传感器。 27. $MOG.A——感觉在机器人领域、spacex供应链里到处都能看到它们 28. $MSFT——在$375这个价位，有一天我们会回头看发现这是买入机会。 29. $CVX——战争结束后油价可能会崩，但这些石油公司将变得极其重要，尤其是委内瑞拉还是个金矿。 30. $XLU——我认为降息可能会重启，我们需要电力/电网来支持AI，所以从$CEG到$NEE这些名字将始终重要。 只是顺便抛出一些除了$AAOI和$AEHR之外的想法。
英文原文
Here's a bunch of random 30 US-available random stocks I like today and why: 1. $INTC - America's hope for foundry, national security 2. $MRVL - scales rev from future maia asics and add ons like cpo, they do everything lost count 3. $TSM - backbone of semis/ai 4. $COHR - They do everything vertically integrated + captures optical cycle 5. $RKLB - the final frontier of space will be around 5 years from now and 20 years from now. 6. $DRAM - memory exposure for samsung/sk hynix 7. $AVGO - hyperscalers dont like nvidia gpu tax 8. $AMZN - nobody can compete against the overnight shipping of toilet paper. robotics will lower opex over time 9. $ARM - AGI CPUs scale revenue quite a bit over the next decade 10. $TSEM - you're going to need a foundry for light based stuff 11. $IBIT - bitcoin, we all know by now 12. $NBIS - i think it's the next AWS. Also they do self-driving cars with uber, own scaling DB companies, data labeling. It's almost like a mini Google. 13. $GOOGL - youtube is not going away, gemini is great. they're vertically integrated with TPUs and fund buildout with operating income so i like it. 14. $AMKR - super facilities coming online in late 2027-2028. benefits from made in america 15. $HOOD - i dont like short term, but long term i'm a fan of Robinhood since they captured retail + have more products like banking, etc that they're scaling up. product innovation is wild. 16. $CRCL - I happen to really like stablecoins and see them as the future for both payments/holding (depends on clarity act) 17. $META - people aren't going to stop using instagram or whatsapp, or others anytime soon. 18. $LITE - $GOOGL TPU exposure decently high part of BOM. As long as Google's AI program keeps running I think $LITE will do well. 19. $LPTH - Germanium and China export controls will always be an issue so US made engineered alternatives will always be important 20. $FN - Someone needs to assemble optical stuff 21. $JBL - same as above, but added with ip from Intel's SiPh acqusition so might end up like innolight? 22. $MP - American rare earths program is extremely important, similar to $INTC national security risks 23. $HIMS - Okay here me out they just acquired a ton of companies, and at $19 they have global DTC channel. short sellers really hate this company, but I think it's actually promising as a contrarian long 24. $SMTC - LRO/LPO transition 25. $POWL - US alternative to hammond for switchgear DC type bottleneck 26. $VPG - Humanoids will be a thing down the road maybe 2027-2028, this makes the sensors. 27. $MOG.A - Feels like i see them everywhere in robotics, to spacex supply chains 28. $MSFT - At $375, one day we'll look back and see this as a buying opportunity. 29. $CVX - oil might crash after war but these oil companies are going to be extremely important, especially when Venezulea is a goldmine. 30. $XLU - i think rate cuts might be back online, we need power/grid for AI so these names will always be improtant from $CEG to $NEE Just throwing out other thoughts aside from $AAOI and $AEHR.
-
看好HIMS与TEM结合布局个性化AI医疗，认为市场潜力巨大
个性化AI医疗很可能是一个巨大的市场。没有人想早死。将 $HIMS 与 $TEM 结合具有巨大潜力。这里有一个GitLab CEO的例子：2023年，Sijbrandij被诊断出骨肉瘤；2024年7月，他宣布癌症复发了，尽管进行了多种治疗；到2024年底，他已经用尽了标准医疗方案的全部选择。没有选择接受死亡，Sijbrandij决定像构建GitLab一样将他的癌症作为一个工程问题来处理。他开始向ChatGPT输入大量的个人医疗数据，包括扫描结果、血液检测结果和组织样本数据。ChatGPT和AI在识别突变后提出了新的靶向治疗方案，然后确定如何攻击这些突变。在此基础上，他申请了未获批准、处于试验阶段的药物并获得了用药。这个方法奏效了。Sijbrandij用AI阻止并扭转了晚期预判。我们已经看到了这个成功案例（ $TEM 明确列为他用于肿瘤批量RNA测序的合作伙伴）。最近也有一个人用AI治愈了自己的狗。如果你能够将 $HIMS（直销医疗分销网络）和 $TEM（个性化测序和AI治疗）结合成一个可扩展的产品，潜力是巨大的（尽管极具挑战性）。全球人口都是潜在市场。这类似于 $AXTI InP（磷化铟）在超大规模数据中心的情况：人们会不惜代价避免死亡（这就是瓶颈）。这只是未来医疗发展方向的一个缩影。
英文原文
Personalized AI medicine will likely be huge. Nobody wants to die early. Combining $HIMS to $TEM has immense potential. Here's just one example with Gitlab's CEO: > In 2023, Sijbrandij was diagnosed with osteosarcoma > In July 2024, he announced the cancer had returned, despite multiple treatments > By late 2024, he had reached the absolute end of standard of care medical options. > Rather than accepting death, Sijbrandij decided to treat his cancer the same way he built GitLab as an engineering problem > He began feeding ChatGPT massive amounts of his personal medical data from scans, blood test results, and tissue sample data. > ChatGPT and AI made novel targeted treatments after identifying mutations, then how to attack them > From there, he applied for unapproved, experimental drug and received it > The approach worked. Sijbrandij managed to stall and turn around a terminal prognosis with AI. We've seen this success story with Gitlab's CEO ( $TEM was explicitly listed the partner he used for the bulk RNA sequencing of his tumor ). As well as someone curing their own dog with AI recently. The potential if you can combine $HIMS (DTC distribution network) and $TEM (Personalized sequencing and AI treatment) into a scalable product is massive (though extremely challenging). The entire human population is the TAM. And similar to the $AXTI InP situation with hyperscalers: People will pay anything to not die (bottleneck). This is just a hint into where the future of healthcare is heading.
-
认为诺和诺德撤诉并合作 HIMS 让很多人措手不及
@alc2022 这事说得通，不过 $NVO 撤诉并转而和 $HIMS 合作，对大多数人来说确实是个意外。 这一下明显打了很多人一个措手不及，尤其是那些没回补、还以为 $HIMS 会完蛋的做空者。
英文原文
@alc2022 Makes sense though given $NVO dropping the lawsuit and partnering with $HIMS was a surprise to majority of people. Definitely caught a lot of people off guard, especially short sellers that didn’t cover and thought $HIMS was going under
-
Huberman 点名 HIMS，进一步强化多头叙事
斯坦福神经科学家 Andrew Huberman，也是健康领域最有影响力的人物之一，刚刚公开点名了 $HIMS。 他还说，在一个非常现实的情景下，它有望“腾飞”。 不是每天都能看到这种“行走的医学广告牌”隐性在给 $HIMS 站台做多。 我很好奇，那些还在做空 41%+ 流通盘的人到底在想什么？
英文原文
Andrew Huberman, the Stanford neuroscientist and one biggest voices in the health, just spotlighted $HIMS. And said it was set to “soar” in a very realistic scenario. Not everyday do you have the walking billboard of medicine implicitly pitching $HIMS as a long. Curious what short sellers were thinking selling 41%+ of the float short?
-
从基本面角度看 HIMS，但空头挤压风险很高
我一直想从基本面角度聊 $HIMS。 但有一点必须强调： $HIMS 的方向性空头现在像被困住了。 股价已经涨了 64.15%，到 26.5 美元了（虽然仍比 70 多美元的高点低）。 与此同时，空头持仓却增加到了创纪录的 41.6%。 这可能会形成剧烈的反馈回路，因为空头会越来越浮亏。 不过，这一切都取决于股价能否继续被买盘和基本面改善推高；只有这样，他们才会被迫平仓。 否则如果价格横盘，他们可以在很长时间里继续维持空头头寸（借券成本也低），然后慢慢回补。 话虽如此，我个人还是在场，挺期待看看 $HIMS 能交出什么： 一方面是最近类似 $META 的全球并购扩张； 另一方面是类似 $HOOD 的交叉销售潜在收入机会。 随着 $HIMS 在 $NVO 意外合作之后基本面快速改善，我个人真的觉得它有机会创造历史。
英文原文
I try to talk about $HIMS from a fundamental standpoint. But this cannot be understated: $HIMS directional shorts look trapped. The stock price is now up 64.15% to $26.5 (still down from highs of $70s). While short interest increased to record highs of 41.6%. There may be a violent feedback loop as short positions go more underwater. However; this is contingent on the underlying stock going up from buying pressure and increasing fundamentals. In order for their positions get liquidated. Otherwise, if prices stagnates, they can leave their short sales in for extended periods of time (low borrow rate) and slowly buy to cover. That being said, I'm personally along for the ride and looking forward to seeing what $HIMS can deliver: Both from their recent $META-like global acquisitions spree + $HOOD-like cross selling latent revenue opportunities. With $HIMS rapidly improving fundamentals, from the surprise $NVO partnership: I personally see a real opportunity for $HIMS to make history.
-
列出自己最喜欢的一篮子名字
@jaegerjaque7 $SOI、$AAOI、SK 海力士、$RDDT、$HIMS
英文原文
@jaegerjaque7 $SOI, $AAOI, SK Hynix, $RDDT, $HIMS
-
认为做空 HIMS 是极其愚蠢的
做空者方向性加仓 $HIMS，真是蠢到家了。 他们最近的收购直接给 $HIMS 带来了全球 DTC 医疗零售市场。 交叉销售机会极其潜在，而且很难建模。 在这种情况下，这根本不是你平常那种有对冲的套利交易，所以风险管理非常差。
英文原文
Extremely stupid for short sellers to directionally double down on $HIMS. Their recent acquisitions just gave $HIMS the global retail market for DTC healthcare. The cross selling opportunities are extremely latent and hard to model. So very bad risk management, given it’s not your typical hedged arbitrage trade.
-
继续看多 HIMS 的商业化潜力与空头挤压
$HIMS 现在又涨回了 14.22%。 他们全球 DTC 零售分发护城河中尚未释放的潜在收入极其惊人。 这也让人联想到 $META 早期的并购，以及 $HOOD 的交叉销售能力。 $HIMS 仍然比 70 多美元的高点低不少，但它已经通过收购三家全球主要竞争对手，而且几乎没有监管阻力。 更妙的是：那些把 40%+ 流通盘方向性做空的空头，已经被 $NVO 的意外合作和诉讼终止彻底困住了。 我个人会在这里继续持有并做多 HIMS。 如果管理层真能把这张全球零售分发网络有效变现，用在医疗上，这个风险回报是值得的。
英文原文
$HIMS is now back up 14.22%. The untapped latent revenue from their their global DTC retail distribution moat is extreme. And draws parallels to the early acquisitions from $META. As well as the cross-selling capabilities of $HOOD. $HIMS is still down from it's $70+ highs, after acquiring three major global competitors without regulatory friction. And best of yet: Shorts that sold 40%+ of the company short directionally, are completely trapped from the surprising $NVO partnership + lawsuit termination. I would personally hold and go long here on HIMS. The risk/reward on management effectively monetizing that massive, global retail distribution network for healthcare seems worth it.
-
用 Cramer 反向指标串起一串当日强势股
Jim Cramer：“今天就是没法赚钱的一天。” 当天： $AXTI：+15.08% $AAOI：+11.5% $HIMS：+6.05% $LITE：+7.06% $SNDK：+6.12% $IQE：+19.08% SK 海力士：+4.38% $MU：+4.65% $COHR：+4.86% 这和前一个帖子里周日提到的“150-200 美元原油”呼应上了。 Cramer 指标又一次显灵了。
英文原文
Jim Cramer: “Just impossible Day to Make Money”. Today: $AXTI: +15.08% $AAOI: +11.5% $HIMS: +6.05% $LITE: +7.06% $SNDK: +6.12% $IQE: +19.08% SK Hynix: 4.38% $MU: +4.65% $COHR: +4.86% This is following the previous post about “$150-200” Oil on Sunday. The Cramer indicator strikes again.
-
HIMS估值核心在于其DTC分销网络，类比HOOD的规模化效应。
是的，围绕 $HIMS 销售的个别产品存在大量看空/看多案例的讨论。 我认为分析师/市场的方法错了： 我认为 $HIMS 的主要估值来源于其通过最近3次收购建立的独特全球零售直接面向消费者(DTC)分销网络。 这解锁了大量潜在收入流+变现机会，就像 $HOOD 为金融行业规模化所做的那样。
英文原文
Yes there's a lot of bear/bull case discussion around individual products $HIMS sells. I think analysts/markets are approaching it wrong: $HIMS main valuation I see is derived from their unique global retail DTC distribution network that they now have with their 3 recent acquisitions. This unlocks a lot of latent revenue stream + monetization, like what $HOOD did for the financial industry to scale.
-
从分销网络和零售捕获角度评估HIMS估值。
@RawlJohns 我纯粹是从他们的分销网络(Distribution Network) + 零售捕获(Retail Capture)角度来看待 $HIMS 的估值。并不是看他们销售的单颗药丸，所以不太确定。
英文原文
@RawlJohns I'm purely looking at $HIMS valuation from their distribution network + retail capture angle. Not the individual pills they sell, so not sure.
-
类比META和HOOD，看好HIMS全球DTC网络变现潜力。
难道没人看到 $HIMS、$META 和 $HOOD 之间的相似之处吗？ $HIMS 真的刚刚收购了全球最大的几家竞争对手： - Zava（欧洲/英国） - Livewell（加拿大） - Eucalyptus（澳大利亚/日本） 而且没有被反垄断阻止？ $META 十年前收购 WhatsApp 和 Instagram 这类公司时，也是几乎没有遇到阻力。 如今，由于 $META 最终成为万亿美元级垄断企业后留下的监管 PTSD，社交媒体公司已经不能再四处大举收购。 而 $HIMS 在这一轮并购之后，已经成为全球最大的独立零售 DTC（直接面向消费者）分销网络。 现在它只需要弄清楚，如何像 $HOOD 面向金融产品那样做交叉销售？ $HOOD 此前也遇到过 SEC 和 Gary 试图阻止其所有加密产品的情况。但自从监管麻烦清除后，他们通过向零售用户交叉销售金融科技产品，成功扩张成了一家700亿美元公司。 我看到了 $NVO / 监管机构试图阻止 $HIMS 产品供应之间的强烈相似之处。 不过，在 $NVO 与 $HIMS 达成合作、FDA 也撤回威胁后，这种监管不确定性已经消除。潜力是存在的？ 我不可能是唯一一个看到 $HIMS 全球 DTC 零售分销网络及其潜在收入变现机会的人吧？
英文原文
Does nobody else see the parallels to $HIMS and $META and $HOOD? $HIMS literally just bought out the largest players around the world: - Zava (Europe/UK) - Livewell (Canada) - Eucalyptus (Australia/Japan) Without antitrust blocking it? $META did that a decade ago with companies like WhatsApp and Instagram with minimal friction. Now no social media company anymore can go on buying sprees due to regulator PTSD after $META ended up a trillion dollar monopoly. $HIMS now is the largest independent global retail DTC distribution network in the world, after their M&A spree. And just needs to figure out how to cross-sell products like what $HOOD did for financial products? $HOOD previously had the SEC + Gary trying to block all their crypto offerings. But ever since they got regulatory headaches cleared up, they managed to scale to become a $70B company off cross-selling fintech products to their retail audience. I'm seeing strong parallels to $NVO / Regulators trying to block $HIMS product offerings. However, that regulatory uncertainty is now cleared up after $NVO partnered with $HIMS and FDA dropped their threats. The potential is there? I can't be the only one who sees potential from $HIMS global DTC retail distribution network and latent revenue monetization?
-
分析$HIMS收购潜力及变现依赖管理层执行力
真是出色的分析！我没想到自己会站出来为 $HIMS 辩护，但他们确实成功收购了以下企业：Zava（欧洲/英国）、Livewell（加拿大）、Eucalyptus（澳大利亚/日本）。他们还建立了全球最大规模的医疗保健零售客户网络（retail capture），且未受到联邦贸易委员会(FTC)或监管机构的制裁。这种潜力让人想起 $META 收购 WhatsApp 及其他平台的时期，并结合了 $HOOD 交叉销售(cross-selling)新功能的策略。最终，如何从这个巨大的分销网络中变现，完全取决于管理层的执行力。
英文原文
정말 훌륭한 분석입니다! 제가 나서서 $HIMS 를 옹호하게 될 줄은 개인적으로 꿈에도 몰랐지만, 그들은 실제로 다음 기업들을 인수하는 데 성공했습니다: Zava (유럽/영국) Livewell (캐나다) Eucalyptus (호주/일본) 그리고 세계 최대 규모의 헬스케어 리테일 고객 네트워크(retail capture)를 구축해 냈습니다. 이 모든 것을 FTC나 규제 당국의 제재 없이 해냈죠. 이런 잠재력을 보면 과거 $META 가 WhatsApp과 기타 플랫폼들을 인수했던 때가 확실히 떠오릅니다. 여기에 $HOOD 가 새로운 기능들을 교차 판매(cross-selling)했던 전략이 결합된 모습입니다. 결국, 이 거대한 유통 네트워크를 어떻게 수익화할지 그 방법을 찾아내는 것은 전적으로 경영진의 실행력에 달려 있습니다.
-
看好$HIMS全球并购后的规模及分销优势，类比$META和$HOOD。
不太是吧？Ro 只在美国。$HIMS 在完成对其他全球重量级玩家的一轮并购后，规模要大得多。 这个全球分销网络没有因为反垄断被阻止，这让我看好 $HIMS，因为我看到了十年前 $META 收购潮的相似之处，也看到了 $HOOD 通过交叉销售变现零售用户的能力。
英文原文
Not really? Ro is US only. $HIMS is much larger in scale after their M&A spree of all the other global heavyweights. That global distribution network without any of them getting blocked by antitrust makes me bullish on $HIMS because I see parallels to $META's acquisition spree a decade ago + $HOOD's capacity to monetize retail audience through cross-selling.
-
区分网络效应与资金/服务粘性，解析RDDT、HOOD及HIMS的护城河差异。
这不是网络效应。 像 $RDDT 这样的社交媒体具有网络效应，这就是为什么你不能在一天内用 vibe coding 复制 Reddit 并指望人们使用它。 $HOOD 具有高粘性，因为用户的资金在那里，且难以转出。 $HIMS 具有高粘性，因为更换医疗服务提供商很困难。
英文原文
It's not a network effect. Social media like $RDDT has a network effect, which is why you can't vibe code Reddit in a day and expect people to use it. $HOOD is sticky because people have their money there and it's difficult to transfer off. $HIMS is sticky because it's difficult to switch medical providers.
-
类比Meta，看好HIMS全球并购后的变现潜力
完全同意，我看到 $HIMS 与 $META 十年前收购所有社交媒体公司的平行之处。 这在今天行不通，因为联邦贸易委员会(FTC)会阻止像 $RDDT 这样的公司收购其竞争对手如 $SNAP。 但 $HIMS 完成了一轮全球并购(M&A)热潮，通过收购欧洲的 Zava、加拿大的 Livewell 以及面向澳大利亚/日本的 Eucalyptus，建立了零售医疗分发的垄断护城河。 因此，既然 $HIMS 设法建立了全球零售医疗用户基础……随着监管问题得到解决，存在巨大的潜在收入变现潜力。
英文原文
Absolutely, I see the $HIMS parallel to $META acquiring all the social media companies a decade ago. This wouldn't work today since FTC would block companies like $RDDT acquiring all their competitors like $SNAP. But $HIMS pulled off a global M&A spree, building a monopoly moat over retail healthcare distribution from Zava in Europe, Livewell in Canada, and Eucalyptus for Australia/Japan. So, now that $HIMS somehow managed to build capture the global retail base for healthcare... With regulatory issues cleared up, there's a lot of latent revenue monetization potential.
-
HIMS价值源于分销网络，且成功完成全球DTC并购。
@iraw000 我的观点是，$HIMS 的价值源于其分销网络，类似于 $AMZN 的配送体系，而非其销售的商品（如电脑、书籍）。此外，他们成功在全球范围内收购了主要的医疗 DTC（直接面向消费者）公司，且未遭遇监管阻碍。
英文原文
@iraw000 My argument is that $HIMS value is derived from their distribution network like $AMZN delivery. Not by the drugs they sell (eg. computers, books). And they managed to acquire the major healthcare DTC companies globally without getting blocked.